Identification of CYP2D6 null variants among long-stay, chronic psychiatric inpatients: Is it strictly necessary?

Human Psychopharmacology

Volumn 23, Issue 6, 2008, Pages 533-536

  Fernández Santander, Ana ^a   Santiago, Catalina ^a   Díez Durán, Sarai ^a   González, María ^b   de Castro, Emilia ^b   Guijarro, Jorge ^b   Bandrés, Fernando ^a   Lucia, Alejandro ^a   Gómez Gallego, Félix ^a  

^a UNIVERSIDAD EUROPEA DE MADRID   (Spain)

^b Grupo EP   (Spain)

Author keywords

Pharmacogenomics; Poor metabolizer; Schizophrenia

Indexed keywords

AMISULPRIDE; ANTIDEPRESSANT AGENT; CHLORPROMAZINE; CLOZAPINE; CYTOCHROME P450 2D6; DEBRISOQUINE HYDROXYLASE; HALOPERIDOL; LEVOMEPROMAZINE; NEUROLEPTIC AGENT; OLANZAPINE; OXYGENASE; PAROXETINE; QUETIAPINE; RISPERIDONE; TRIFLUOPERAZINE;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; CAUCASIAN; CONTROLLED STUDY; DRUG DOSE REDUCTION; ETHNICITY; FEMALE; GENE FREQUENCY; GENETIC CODE; GENETIC IDENTIFICATION; GENETIC VARIABILITY; GENOTYPE; HOMOZYGOSITY; HOSPITAL PATIENT; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MENTAL PATIENT; NULL ALLELE; PRIORITY JOURNAL; SCHIZOPHRENIA; SPAIN;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; CHRONIC DISEASE; CYTOCHROME P-450 CYP2D6; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; SCHIZOPHRENIA; VARIATION (GENETICS);

EID: 51049124235     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.943     Document Type: Article

References (24)

1. Agundez J, Martinez C, Ledesma MC, Ladona MG, Ladero JM, Benitez J. 1994. Genetic basis for differences in desibroquin polymorphism between a Spanish and other white populations. Clin Pharmacol Ther 55: 412-417.
2. Arranz MJ, de Leon J. 2007. Pharmacogenetics and phamacogenomics of schizophrenia: a review of the last decade of research. Mol Psychiatry 12: 707-747.
3. Bertilsson L, Dahl ML, Dalen F, Al-Shurbaji A. 2002. Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. Br J Clin Pharmacol 53: 111-122.
4. Bradford LD. 2002. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics 3: 229-243.
5. de Leon J, Armstrong SC, Cozza KL. 2006. Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19. Psychosomatics 47: 75-85.
6. de Leon J, Susce MT, Pan RM, Fairchild M, Koch WH, Wedlund PJ. 2005. The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. J. Clin Psychiatry 66: 15-27.
7. Ellingrod VL, Schultz SK, Arndt S. 2000. Association between cytochrome P450 2D6 (CYP2D6) genotype, antipsychotic exposure, and abnormal involuntary movement scale (AIMS) score. Psychiatr Genet 10: 9-11.
8. Fava M. 2006. Management of nonresponse and intolerance: switching strategies. J. Clin Psychiatry 61 (suppl 2): 10-12.
9. Griese EU, Zanger UM, Brudermanns U, et al. 1998. Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population. Pharmacogenetics 8: 15-26.
10. Hirschfeld RMA, Montgomery SA, Aguglia E, et al. 2002. Partial response and nonresponse to antidepressant therapy: current approaches and treatment options. J. Clin Psychiatry 63: 826-837.
11. Ingelman-Sundberg M. 2005. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J 5: 6-13.
12. Kapitany T, Meszaros K, Lenzinger E, et al. 1998. Genetic polymorphisms for drug metabolism (CYP2D6) and tardive dyskinesia in schizophrenia. Schizophr Res 32: 101-106.
13. Kato D, Kawanishi C, Kishida I, et al. 2005. CYP2D6 gene deletion allele in patients with neuroleptic malignant syndrome: preliminary report. Psychiatry Clin Neurosci 59: 504-507.
14. Kirchheiner J, BrØen K, Dahl ML, et al. 2001. CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psychiatr Scand 104: 173-192.
15. Leathart JB, London SJ, Steward A, Adams JD, Idle JR, Daly AK. 1998. CYP2D6 phenotype-genotype relationships in African-Americans and Caucasians in Los Angeles. Pharmacogenetics 8: 529-541.
16. Masimirembwa CM, Hasler JA. 1997. Genetic polymorphism of drug metabolising enzymes in African populations: implications for the use of neuroleptics and antidepressants. Brain Res Bull 44: 561-571.
17. Menoyo A, del Rio E, Baiget M. 2006. Characterization of variant alleles of cytochrome CYP2D6 in a Spanish population. Cell Biochem Funct 24: 381-385.
18. Mulder H, Wilmink FW, Beumer TL, Tamminga WJ, Jedema JN, Egberts AC. 2005. The association between cytochrome P450 2D6 genotype and prescription patterns of antipsychotic and antidepressant drugs in hospitalized psychiatric patients: a retrospective follow-up study. J. Clin Psychopharmacol 25: 188-191.
19. Ohmori O, Suzuki T, Kojima H, et al. 1998. Tardive dyskinesia and debrisoquirie 4-hydroxylase (CYP2D6) genotype in Japanese schizophrenics. Schizophr Res 32: 107-113.
20. Patsopoulos NA, Ntzani EE, Zintzaras E, Ioannidis JP. 2005. CYP2D6 polymorphisms and the risk of tardive dyskinesia in schizophrenia: a meta-analysis. Pharmacogenet Genomics 15: 151-158.
21. Rasmussen JO, Christensen M, Svendsen JM, Skausig O, Hansen EL, Nielsen KA. 2006. CYP2D6 gene test in psychiatric patients and healthy volunteers. Scand J Clin Lab Invest 66: 129-136.
22. Sachse C, Brockmöller J, Bauer S, Roots I. 1997. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotype consequences. Am J Hum Genet 60: 284-295.
23. Scordo MG, Spina E, Romeo P, et al. 2000. CYP2D6 genotype and antipsychotic-induced extrapyramidal side effects in schizophrenic patients. Eur J Clin Pharmacol 56: 679-683.
24. Steimer W, Zöpf K, von Amelunxen S, et al. 2005. Amitriptyline or not, that is the question: pharmacogenetic testing of CYP2D6 and CYP2C19 identifies patients with low or high risk for side effects in amitriptyline therapy. Clin Chem 51: 376-385.